$ PSID. PositiveID Corporation Announces 2016 Highlights
DELRAY BEACH, Fla., Feb. 21, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today a summary of its 2016 highlights for its molecular diagnostics, mobile labs, and medical device businesses.
Firefly Dx Highlights
•Proved its Firefly Dx breadboard prototype pathogen detection system ("prototype system") functions as intended through the complete sample purification and detection process
•Successfully detected Zika virus on the Firefly Dx prototype system, which also detects Ebola, MRSA, MSSA, C. diff, E. coli, influenza and other pathogens
•Awarded a follow-on contract from the U.S. Department of the Interior on behalf of the U.S. Department of Homeland Security Science & Technology Directorate for the SenseNet Program Phase II, to use Firefly Dx in conjunction with its partner ENSCO
•Successfully detected genetically modified organisms on the Firefly Dx prototype system during a pilot study with seqID inc.; results were consistent with the industry-standard, lab-based equipment used to detect the GMOs during the pilot study
E-N-G Mobile Systems Highlights ("ENG")
•Shipped a mobile lab worth in excess of $700,000 to a customer
•Second half vehicle production and modification orders, as well as service business in 2016 more than doubled from the first half
•Focused heavily on building sales in 2016 to start 2017 with over $4.0 million of orders in backlog and pipeline, including a recently announced purchase order for $1.2 million for mobile labs
Thermomedics and Caregiver®
•Signed seven new acute care medical specialty distributors for its FDA-cleared Caregiver non-contact, infrared thermometer in 2016, bringing the total to nine for the U.S.
•Won appeal in patent infringement case in U.S. Court of Appeals in the patent infringement suit brought by Exergen Corporation
•Successfully tested the first Bluetooth®-enabled version of Caregiver
•Announced Caregiver outperformed a temporal artery thermometer during a Veterans Affairs San Diego Healthcare System study of Post Anesthesia Care Unit patients, and exceeded industry laboratory standards for accuracy and showed a high level of agreement in a pediatric study
"We are very proud of the accomplishments made by the PositiveID team in 2016, including building the sales backlog and pipelines to grow these businesses for the future while we pursue a strategic partner to fund the completion of the development and testing of Firefly Dx," said William J. Caragol, Chairman and CEO of PositiveID. "In 2017, we expect to see those efforts continue to take root and pay off, and believe we can expand our businesses both organically and through acquisition in 2017 and beyond."
PositiveID will announce its financial results for the fourth quarter and year ended December 31, 2016 when it files its Form 10-K on or about March 30, 2017.
MY POST IS JUST MY OPINION!!!!
